The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of September 19, 2017.
1. Capricor Therapeutics Inc. (CAPR)
Gained 70.45% to close Tuesday’s (Sep.19) trading at $2.25. This is the second straight day of gain for the stock.
News: No news
— The Company is slated to present six-month follow-up results from the randomized Phase I/II HOPE-Duchenne clinical trial of CAP-1002 in boys and young men with Duchenne muscular dystrophy at the 22nd International Congress of the World Muscle Society on Wednesday, October 4, 2017.
Positive top-line results from a safety and exploratory efficacy analysis of six-month data from the randomized 12-month Phase I/II HOPE Clinical Trial of CAP-1002 were reported on April 25, 2017.
— The top-line 12-month results from the HOPE-Duchenne Trial are expected to be reported in the fourth quarter of 2017.
2. Vascular Biogenics Ltd. (VBLT)
Gained 24.14% to close Tuesday’s trading at $7.20. This is the second straight day of gain for the stock.
New: No news
— A final DSMC review of the Company’s phase III study of VB-111 in patients with recurrent glioblastoma (rGBM), dubbed GLOBE, is expected in late September.
— Top-line data from the GLOBE trial anticipated in Q1 2018.
— Initiation of a phase III study of VB-111 in ovarian cancer by year-end 2017.
— Initiation of exploratory clinical study of VB-111 in combination with a checkpoint inhibitor in lung cancer in Q1 2018.
3. MyoKardia Inc. (MYOK)
Gained 8.17% to close Tuesday’s trading at $48.35.
News: The Company presented additional positive data from the first patient cohort of its phase II study of Mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients, dubbed PIONEER-HCM.
The new data indicated that Mavacamten treatment led to a meaningful reduction, in the first few weeks of treatment, in resting left ventricular outflow tract (LVOT) gradient with a less pronounced reduction in resting left ventricular ejection fraction (LVEF). The rapid reduction in LVOT gradient, observed in 9 out of 10 patients by week 2, supported the addition of a second, low-dose cohort in the PIONEER-HCM trial.
MyoKardia initially reported positive topline results from this first patient cohort on August 7, 2017, which met the primary endpoint of change in post-exercise peak LVOT gradient from baseline to week 12 as well as key…